MedPath

Efficacy of Coordinated Insulin Boluses in Type 1 Diabetic Patients

Phase 4
Completed
Conditions
Type 1 Diabetes
Interventions
Drug: Normal bolus
Drug: Coordinated bolus
Registration Number
NCT02229097
Lead Sponsor
University Hospital, Toulouse
Brief Summary

A recent study suggests that, in Type 1 Diabetes (T1D) patients treated by insulin pumps, a better coordination of meal boluses and post prandial basal rate could reduce the importance of postprandial hyperglycaemias without increasing the risk of delayed hypoglycaemias.

The aim of the investigators study is to assess if these results are confirmed in a clinical trial.

The aim of this study is to compare the efficacy of coordinated boluses versus normal boluses on postprandial glycaemic control of T1D patients treated with continuous subcutaneous insulin infusion.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
17
Inclusion Criteria
  • Type 1 diabetes mellitus
  • with confirmed Negative C-peptide or diabetes duration>5 years
  • Treated by external insulin pump and rapid insulin analog for more than 3 months
  • using a Medtronic Paradigm Real-Time or Veo™ model
  • Educated to and practicing functional insulin treatment and carbohydrate counting for more than 3 months
  • Able to use the "basal temp" and "glycaemia reminder" functions of their pump
  • Basal infusion rate ≥ 0,5 Unit/h
  • Self-monitoring of blood glucose frequency > 4/days
  • Aware of hypoglycaemia
Exclusion Criteria
  • known impaired renal function (creatinin clearance <60ml/min)
  • Gastroparesis
  • Serious or instable disease likely to induce a glycaemic control deterioration - treatment with corticosteroids

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Normal then CoordinatedNormal bolusnormal bolus during 2 weeks then coordinated bolus during 2 weeks
Normal then CoordinatedCoordinated bolusnormal bolus during 2 weeks then coordinated bolus during 2 weeks
Coordinated then NormalNormal boluscoordinated bolus during 2 weeks then normal bolus during 2 weeks
Coordinated then NormalCoordinated boluscoordinated bolus during 2 weeks then normal bolus during 2 weeks
Primary Outcome Measures
NameTimeMethod
postprandial glycaemia2 hours after eating during 4 weeks

measured by Self Monitoring of Blood Glucose

Secondary Outcome Measures
NameTimeMethod
mean glycaemiabefore eating and 2 hours after eating during 4 weeks

data from Self Monitoring of Blood Glucose

adverse eventsThroughout the study (4 weeks)
severe hypoglycaemia frequencyThroughout the study (4 weeks)
insulin dosesbasal rate and boluses
frequency of glycaemia < or = 60mg/dlbefore eating and 2 hours after eating during 4 weeks

data from Self Monitoring of Blood Glucose

frequency of glycaemia between 61-140mg/dlbefore eating and 2 hours after eating during 4 weeks

data from Self Monitoring of Blood Glucose

standard deviation of glycaemiabefore eating and 2 hours after eating during 4 weeks

data from Self Monitoring of Blood Glucose

frequency of glycaemia >140mg/dlbefore eating and 2 hours after eating during 4 weeks

data from Self Monitoring of Blood Glucose

mean glycemiaThroughout the day during 4 weeks

data from Continue Glycemia Monitoring

standard deviationThroughout the day during 4 weeks

data from Continue Glycemia Monitoring

time spent within glucose range < or = 60mg/dlThroughout the day during 4 weeks

data from Continue Glycemia Monitoring

time spent within glucose range between 61-140mg/dlThroughout the day during 4 weeks

data from Continue Glycemia Monitoring

time spent within glucose range mg/dlThroughout the day during 4 weeks

data from Continue Glycemia Monitoring

fructosamineday 1 + 4 weeks

Trial Locations

Locations (3)

Saint-André Hospital

🇫🇷

Bordeaux, France

Lapeyronie Hospital

🇫🇷

Montpellier, France

University Hospital Toulouse Rangueil

🇫🇷

Toulouse, Haute Garonne, France

© Copyright 2025. All Rights Reserved by MedPath